# Pentostatin, Alemtuzumab, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

> **NCT00669318** · PHASE2 · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 41 (actual)

## Conditions studied

- Leukemia
- Lymphoma

## Interventions

- **BIOLOGICAL:** alemtuzumab
- **BIOLOGICAL:** rituximab
- **DRUG:** pentostatin
- **DRUG:** sargramostim

## Key facts

- **NCT ID:** NCT00669318
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-07
- **Primary completion:** 2013-05
- **Final completion:** 2014-05
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2014-07-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00669318

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00669318, "Pentostatin, Alemtuzumab, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT00669318. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*